News Headlines

  1. Samsung Bioepis Enters Into Partnership Agreement With Sandoz For Up To Five Next-Generation Biosimilar Candidates 3/18/2026

    Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under development by Samsung Bioepis, including SB36, a biosimilar candidate referencing Entyvio1 (vedolizumab).

  2. Viral Vector Manufacturing (VVMF) Enters Into Licensing Agreement With OXB, Gaining Access To The OXB AAV And LV Viral Vector Platforms 3/18/2026

    Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a licensing and option agreement with OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO.

  3. New England Biolabs® Releases EnClose™ Cell-Free dbDNA™ Synthesis Kit In Collaboration With Touchlight To Accelerate DNA And RNA Therapeutic Development 3/18/2026

    New England Biolabs (NEB®) today announced the release of the EnClose Cell-free dbDNA Synthesis Kit, developed in collaboration with Touchlight.

  4. BioCina Initiates Comprehensive Manufacturing Program For Patrys' Proprietary Injectable Therapeutic To Alleviate Delirium 3/17/2026

    BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care settings.

  5. Alebund Pharmaceuticals Announces Collaboration And License Agreement With R1 Therapeutics For AP306 3/17/2026

    Alebund Pharmaceuticals ("Alebund" or the "Company"), a leading renal-focused biopharmaceutical company, today announced that it has entered into licensing and equity agreements (the "Agreements") with R1 Therapeutics, Inc. ("R1"). R1 is a newly launched clinical-stage biotechnology company that recently completed an oversubscribed Series A financing of $77.5M.

  6. Celltrion Signs Supply Agreement With A Global Biopharma Worth Up To KRW 375.4 Billion, Reflecting Recognition Of Product Quality And Manufacturing Productivity, And Accelerating CDMO Growth 3/17/2026

    Celltrion announced today that it has signed a contract manufacturing (CMO) agreement with a global pharmaceutical company for the supply of drug substance. The counterparty remains undisclosed to ensure business confidentiality.

  7. Cellipont Bioservices And BobcatBio Announce Strategic Collaboration To Advance Macrophage Cell Therapy For Solid Tumors 3/17/2026

    Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with BobcatBio, a clinical-stage biotechnology company that is pioneering the development of RB-1355, a first of its kind cellular therapy that leverages the versatility and power of a patient's macrophages to elicit a robust, targeted tumoricidal immune response while substantially reducing or eliminating the reliance on traditional cancer treatments such as chemotherapy, high-dose radiation and surgery, thereby improving patient outcomes and quality of life.

  8. CEO Insights And Trends: The Future Of The Sterile Filling CDMO Industry 3/17/2026

    Denis Johnson, CEO, explores developments in the CDMO sector and reveals how GRAM is gearing up for its latest phase of growth in sterile filling.

  9. OPTEL And Kaster Technologies Partner To Bring AI-Driven Production Planning Intelligence To Pharma 3/17/2026

    OPTEL, a global leader in traceability and compliance solutions, and Kaster Technologies, a specialist in AI-powered production planning intelligence software, have announced a strategic commercial partnership to help pharmaceutical manufacturers increase production capacity and improve operational efficiency.

  10. Apertura Gene Therapy And Viralgen Announce Strategic Collaboration To Manufacture TfR1 CapX, A Next-Generation Capsid For Gene Therapies Designed To Treat Central Nervous System Diseases 3/17/2026

    Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, today announced a strategic manufacturing collaboration to support gene therapy programs using Apertura's TfR1 CapX, a novel AAV capsid that targets human Transferrin Receptor 1 (hTfR1) to cross the blood-brain barrier.